Celebrex In Acute Gouty Arthritis Study

Arthritis, Gouty Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis

Status Completed

Clinical Trial Summary

This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00549549
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	February 2008
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05119686` - Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 2
Recruiting	`NCT06439602` - Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 3
Active, not recruiting	`NCT05253833` - Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout	Phase 2
Not yet recruiting	`NCT05966701` - The MAD Study of SSGJ-613 in Healthy Subjects	Phase 1
Completed	`NCT00663169` - Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout	Phase 2